a Nationwide PEM.
* there are related drugs with significant problems;
* the target disease is of low risk and any increased risk arising from therapy would adversely affect the benefit-risk balance;
* safe treatment options are already available and any increase in risk would be unacceptable;
* another drug of the same class is being monitored or considered, which provides the added value of a comparator and also raises the question of equity for the sponsors.
Was this article helpful?